智通财经APP获悉，摩根大通发表研究报告指出，2025年香港上市的保险股表现优于亚太区同业，其中国人寿(02628)升87%，跑赢恒指28%的升幅。该行预期，2026年将是主要寿险公司强劲资产负债表、稳健分销渠道及优化产品组合获得市场认可的一年。中国平安(02318)为该行首选，给予“增持”评级，目标价上调至100港元。其次为中国人寿(02628)，目标价40港元。
该行同时将太保(02601)评级由“中性”上调至“增持”，反映其基本面复苏。不过，将新华保险(01336)评级由“增持”下调至“中性”，主要由于2025年股价强劲上涨后，相对主要寿险公司的准备金质量差距扩大。
对于非寿险板块，该行维持谨慎立场，对人保(01339)及财险(02328)维持“中性”评级。该行继续偏好H股多于A股，认为H股具有更有利的风险回报状况，预计H-A股估值差距将会收窄。中国平安(02318)以2026财年预测市盈率7倍及5%股息率交易，估值吸引。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.